The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1219
October 10, 2005
View Complete Issue         Table of Contents 2019 
Second-Generation Antipsychotics - Aripiprazole Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Second-Generation Antipsychotics - Aripiprazole Revisited
October 10, 2005 (Issue: 1219)
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Second-Generation Antipsychotics - Aripiprazole Revisited
Article code: 1219a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.